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Abstract
Background: African children have some of the highest rates of bacterial meningitis in the world.
Bacterial meningitis in Africa is associated with high case fatality and frequent neuropsychological sequelae.
The objective of this study is to present a comprehensive review of data on bacterial meningitis sequelae
in children from the African continent.
Methods: We conducted a systematic literature search to identify studies from Africa focusing on
children aged between 1 month to 15 years with laboratory-confirmed bacterial meningitis. We extracted
data on neuropsychological sequelae (hearing loss, vision loss, cognitive delay, speech/language disorder,
behavioural problems, motor delay/impairment, and seizures) and mortality, by pathogen.
Results: A total of 37 articles were included in the final analysis representing 21 African countries and
6,029 children with confirmed meningitis. In these studies, nearly one fifth of bacterial meningitis survivors
experienced in-hospital sequelae (median = 18%, interquartile range (IQR) = 13% to 27%). About a quarter
of children surviving pneumococcal meningitis and Haemophilus influenzae type b (Hib) meningitis had
neuropsychological sequelae by the time of hospital discharge, a risk higher than in meningococcal
meningitis cases (median = 7%). The highest in-hospital case fatality ratios observed were for
pneumococcal meningitis (median = 35%) and Hib meningitis (median = 25%) compared to meningococcal
meningitis (median = 4%). The 10 post-discharge studies of children surviving bacterial meningitis were of
varying quality. In these studies, 10% of children followed-up post discharge died (range = 0% to 18%) and
a quarter of survivors had neuropsychological sequelae (range = 3% to 47%) during an average follow-up
period of 3 to 60 months.
Conclusion: Bacterial meningitis in Africa is associated with high mortality and risk of neuropsychological
sequelae. Pneumococcal and Hib meningitis kill approximately one third of affected children and cause
clinically evident sequelae in a quarter of survivors prior to hospital discharge. The three leading causes of
bacterial meningitis are vaccine preventable, and routine use of conjugate vaccines could provide
substantial health and economic benefits through the prevention of childhood meningitis cases, deaths and
disability.
Published: 14 September 2009
BMC Medicine 2009, 7:47 doi:10.1186/1741-7015-7-47
Received: 19 August 2009
Accepted: 14 September 2009
This article is available from: http://www.biomedcentral.com/1741-7015/7/47
© 2009 Ramakrishnan et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medicine 2009, 7:47 http://www.biomedcentral.com/1741-7015/7/47
Page 2 of 17
(page number not for citation purposes)
Background
Bacterial meningitis is a serious, often disabling and
potentially fatal infection resulting in 170,000 deaths
worldwide each year [1]. Young children are particularly
vulnerable to bacterial meningitis, and when exposed
poor outcomes may occur due to the immaturity of their
immune systems. Two thirds of meningitis deaths in low-
income countries occur among children under 15 years of
age [2]. The main bacterial pathogens causing meningitis
beyond the neonatal period are Streptococcus pneumoniae
(pneumococcus), Haemophilus influenzae type b (Hib) and
Neisseria meningitidis (meningococcus) [3-5]. Pneumococ-
cal meningitis is associated with the highest case fatality
ratios (CFRs) globally [6]. In Africa, pneumococcal men-
ingitis CFRs attain 45% compared to 29% for Hib menin-
gitis and 8% for meningococcal meningitis [3].
Serious, long-term neuropsychological sequelae further
increase the population impact of paediatric meningitis.
Sequelae comprise a range of findings with implications
for child development and functioning and include such
deficits as hearing loss, vision loss, cognitive delay,
speech/language disorder, behavioural problems, motor
delay/impairment, and seizures [7,8]. Meningitis sequelae
can present a long-term, serious hardship for families with
limited means to care for a disabled child, especially in
resource-poor settings.
Africa experiences a disproportionately large burden of
meningitis due to its young population, epidemics in the
meningitis belt and high rates of endemic disease. The
incidence and CFRs associated with paediatric Hib and
pneumococcal meningitis were highest in Africa com-
pared to all other regions in a recent global review [9]. In
addition, Africa is the only region with cyclic epidemics of
meningitis that affect persons of all ages, with attack rates
ranging from 100 to 800 per 100,000 population [10].
Epidemics of meningitis are mostly associated with
meningococcus, but there is some evidence that increases
in pneumococcal meningitis cases occur in parallel during
the hot and dry season [11-13].
A safe and effective Hib conjugate vaccine is available and
routinely used in most African countries. Pneumococcal
vaccines are gradually being introduced with support
from the Global Alliance for Vaccines and Immunisation
(GAVI), and meningococcal vaccines will soon become
available. Together with mortality, morbidity due to in-
hospital and long-term neuropsychological sequelae must
be incorporated into estimates of the burden of meningi-
tis to evaluate the potential benefit of preventive efforts
such as conjugate vaccines.
The objective of this paper is to present a systematic
review of the sequelae following acute bacterial meningi-
tis in African children between the ages of 1 month and 15
years. Several earlier reviews have examined mortality
associated with bacterial meningitis [3,9]. This review
focuses on studies with primary data on neuropsycholog-
ical sequelae due to bacterial meningitis.
Methods
Literature search strategy
We conducted a systematic literature search for articles
published between January 1980 and August 2008 con-
taining information on bacterial meningitis among chil-
dren from continental Africa. Professional librarians
searched eight databases: PubMed/Medline, Global
Health Database, Embase, Biological Abstracts, Pascal,
Current Contents, the Cochrane Library, and African
Index Medicus. Search terms were based on the key words
'meningitis' and at least one of the following: bacteria,
bacteraemia, Streptococcus pneumoniae, Haemophilus influ-
enzae type b, or Neisseria meningitidis (see Additional file 1
for full search strategy). We also screened the reference
lists of two global reviews for articles with published or
unpublished data [5,9]. Citations were uploaded into an
EndNote XI library (EndNote, Carlsbad, CA, USA) and de-
duplicated.
Citation screening
Two screeners reviewed each citation by preset inclusion
and exclusion criteria; discrepancies were resolved
through a weekly conference call. We only included arti-
cles with original sequelae data on at least 30 paediatric
cases of laboratory-confirmed bacterial meningitis from 1
or more African countries. Laboratory-confirmed bacterial
meningitis was defined as bacterial identification in cere-
brospinal fluid (CSF) by culture, Gram stain, rapid anti-
gen test (such as the Binax NOW test (Binax Inc.,
Scarborough, ME, USA)), latex agglutination or polymer-
ase chain reaction, or bacterial isolation from blood cul-
ture accompanied by CSF abnormalities such as high
white blood cell count, low glucose or high protein. We
accepted the article definitions of CSF abnormalities,
including CSF white blood cell count greater than 10 to
100 cells/mm3, protein greater than 0.3 to 2 g/l, and CSF
glucose less than 0.2 g/l or CSF glucose: blood glucose
ratio lower than 0.5. Articles had to present sequelae data
separately for children or have a majority of their subjects
between the ages of 1 month and 15 years. Articles in all
languages were considered for inclusion.
Data extraction
Detailed information on neuropsychological sequelae
was collected and entered into a Microsoft Access database
(Microsoft, Redmond, WA, USA). Sequelae included hear-
ing loss, vision loss, cognitive delay (including mental
retardation and learning disability), speech/language dis-
order, behavioural problems, motor delay/impairmentBMC Medicine 2009, 7:47 http://www.biomedcentral.com/1741-7015/7/47
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(including gross motor and fine motor impairment,
impaired activities of daily living, hypertonia, and paraly-
sis), seizures, and other neurological sequelae. In-hospital
sequelae and deaths were defined as events that occurred
after the initiation of treatment and prior to discharge,
exclusive of complications observed at the time of admis-
sion. Post-discharge sequelae and deaths were defined as
events that occurred or persisted after discharge as
detected upon follow-up tracing of patients. Unless there
was specific mention of patient follow-up after discharge,
we assumed that sequelae were assessed in hospital.
We examined articles for overlaps in study population
and outcomes: when these occurred, one article in the
overlapping group was excluded or the outcomes partially
extracted to avoid double counting cases. We also evalu-
ated the consistency of papers by verifying that the num-
bers presented in the results section added up to the total
subjects and total meningitis cases. If there were major or
numerous inconsistencies in a paper, it was excluded from
the final analysis.
Data analysis
The final database was transferred into Stata 10.0 for anal-
ysis (Stata, College Station, TX, USA). Outcomes of inter-
est included risk of sequelae among survivors (both in
hospital and post discharge) and case fatality ratios (in
hospital and post discharge). Sequelae and mortality were
calculated separately for pneumococcal, Hib, and menin-
gococcal meningitis, and then for all laboratory-con-
firmed bacterial meningitis. For in-hospital sequelae
prevalence, the denominator included all children surviv-
ing until discharge and evaluated for sequelae; for post-
discharge sequelae prevalence, the denominator included
children surviving until the follow-up visit and evaluated
for sequelae. Case fatality ratios were calculated only for
articles with at least 25 cases of confirmed bacterial men-
ingitis and sequelae risks were calculated only for articles
that assessed at least 25 survivors of bacterial meningitis.
African countries were grouped into regions to match the
Global Burden of Disease analysis [9]: eastern Africa men-
ingitis belt, middle Africa meningitis belt, western Africa
meningitis belt, eastern Africa, middle Africa, western
Africa, northern Africa and southern Africa (Table 1).
Results
Literature search and citation screening
We initially identified 2,268 citations, of which 1,168
remained after de-duplication (Figure 1). All unique cita-
tions were double screened and 1,039 were excluded.
Among these, 43 review articles were identified of which
20 were retrieved in full and checked for pertinent, unique
citations; no new citations were found through this proc-
ess. A total of 43 articles could not be retrieved prior to 1
October 2008 and were hence excluded.
In all, 86 articles were moved forward to the data extrac-
tion phase. Of those articles, 42 were excluded because
they did not present sequelae data separately for labora-
tory-confirmed and unconfirmed cases of bacterial men-
ingitis. An additional 7 articles were excluded due to
inconsistencies in the data presented in the results; thus,
37 articles remained in the final analysis.
Articles included in the review
The 37 included articles present data from 21 different
African countries (Figure 2 and Table 2). A total of 10
studies were conducted during a meningitis epidemic. All
regions contributed some data on in-hospital sequelae.
The western Africa meningitis belt region had the most
data, with 12 articles including 2,394 cases of confirmed
bacterial meningitis (CBM) with known outcomes, while
southern Africa had the least, with 2 articles including 140
cases of CBM with known outcomes (Table 3). Post-dis-
charge sequelae data were more limited, and originated
from only seven countries in northern Africa or the men-
ingitis belt. Only 1,131 children with any type of CBM
were assessed for post-discharge sequelae.
Table 1: List of countries by African region
Region Countries
Africa Eastern Meningitis Endemic Eritrea, Ethiopia, Kenya, Sudan, Uganda
Africa Middle Meningitis Endemic Cameroon, Central African Republic, Chad
Africa Western Meningitis Endemic The Gambia, Ghana, Senegal, Togo, Benin, Burkina Faso, Cote d'Ivoire, Guinea, Guinea-Bissau, Mali, 
Mauritania, Niger, Nigeria
Africa Eastern Mauritius, Seychelles, Comoros, Djibouti, Madagascar, Zimbabwe, Burundi, Malawi, Mozambique, Rwanda, 
Somalia, United Republic of Tanzania, Zambia
Africa Middle Congo, Gabon, Angola, Democratic Republic of Congo, Equatorial Guinea
Africa Western Cape Verde, Sao Tome and Principe, Liberia, Sierra Leone
Africa Northern Libya, Tunisia, Algeria, Egypt, Morocco
Africa Southern Namibia, South Africa, Botswana, Lesotho, Swaziland
African countries are grouped into eight regions, based on the groupings used in the Global Burden of Disease analysis [9].BMC Medicine 2009, 7:47 http://www.biomedcentral.com/1741-7015/7/47
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In-hospital sequelae and mortality
All causes of CBM
In all, 27 articles reported in-hospital mortality data for 25
or more children with CBM (4,245 total cases); 24 of
these articles also had sequelae data for at least 25 child
survivors (2,971 total cases) (Table 4). Most studies (23 of
37, or 62%) included pneumococcus, Hib, and/or menin-
gococcus. Nine studies also included other bacterial path-
Citations found through literature search Figure 1
Citations found through literature search.
Identify unique citations
N=1168
Apply screening criteria
Obtain full text
N=109
Not enough information
N=152
Include
N=86 Not enough information &
Unable to retrieve full article
N=43
Exclude
N=1039
Review article
N=43
Obtain full text 
N=20
Check references
Extract data
N=86
Article screened out
N=42
Complete data extraction
N=44
Article excluded for inconsistent
numbers or overlapping
study populations
N=7
Article included in final analysis
N=37
Search databases
N=2268BMC Medicine 2009, 7:47 http://www.biomedcentral.com/1741-7015/7/47
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ogens such as Salmonella, enterobacteria, Staphylococcus,
other streptococci, Escherichia coli or Klebsiella. One study
included only tuberculosis (TB) meningitis cases.
Cases were recruited and assessed for sequelae prospec-
tively in 12 of 24 studies and retrospectively in 11 studies.
One study recruited cases retrospectively and assessed out-
comes prospectively. In 20 studies, sequelae were diag-
nosed by clinical exam only.
The risk of in-hospital neuropsychological sequelae (Fig-
ure 3) ranged from 4% to 57% for all causes of bacterial
meningitis combined (median 18%, interquartile range
(IQR) 13% to 27%). A total of 12 studies provided infor-
mation by sequelae type. Hearing loss and motor impair-
ments were most frequently reported, with estimates of
risk ranging from 2% to 33% and 1% to 37%, respectively,
based on 10 studies each. No studies had data on speech
or language problems.
CFRs for all confirmed types of bacterial meningitis
ranged from 1% to 75%, (median 27%, IQR 9% to 34%)
(Figure 4).
Pneumococcal meningitis
A total of 10 studies had data on pneumococcal meningi-
tis sequelae, including 676 children. These studies found
one or more sequelae in 16% to 38% of children (median
25%, IQR 21% to 32%) (Table 5). One study found hear-
ing loss in 5% of cases [14], and another study examining
Table 2: List of articles included in review
Reference First author Year of publication Country Region Total no. of CBM cases
[33] Abid 1999 Morocco Africa Northern 141
[34] Abid 1999 Morocco Africa Northern 118
[35] Akpede 1999 Nigeria Western Meningitis 63
[36] Bijlmer 1990 Gambia Western Meningitis 77
[37] Bissagnene 1996 Cote d'Ivoire Western Meningitis 654
[38] Bernard-Bonnin 1985 Cameroon Middle Meningitis 174
[39,40] Camara 2003 Senegal Western Meningitis 511
[14] Friedland 1992 South Africa Africa Southern 79
[16] Girgis 1991 Egypt Africa Northern 160
[41] Girgis 1989 Egypt Africa Northern 429
[17] Girgis 1998 Egypt Africa Northern 697
[22] Goetghebuer 2000 The Gambia Western Meningitis 257
[42] Grobler 1997 South Africa Africa Southern 61
[43] Hailu 2001 Ethiopia Eastern Meningitis 32
[44] Koko 2000 Gabon Africa Middle 91
[45] Kristos 1993 Ethiopia Eastern Meningitis 124
[46] Lagunju Nigeria Western Meningitis 29
[47] Mackie 1992 Ghana Western Meningitis 69
[48] Mbonda 1995 Cameroon Middle Meningitis 67
[49] Melaku 2003 Ethiopia Eastern Meningitis 53
[50] Mhirsi 1992 Tunisia Africa Northern 98
[51] Molyneux 1998 Malawi Africa Eastern 149
[52] Molyneux 2000 Malawi Africa Eastern 52
[53] Moreau 1986 Cote d'Ivoire Western Meningitis 47
[54] Mwangi 2002 Kenya Eastern Meningitis 224
[55] Ogunlesi 2005 Nigeria Western Meningitis 124
[56] Pelkonen 2008 Angola Africa Middle 403
[57,58] Razafindralambo 2004 Madagascar Africa Eastern 83
[59] Redjah 1998 Algeria Africa Northern 57
[60,61] Salih 1990 Sudan Eastern Meningitis 43
[62] Salih 1990 Sudan Eastern Meningitis 108
[63] Sangare 2005 Burkina Faso Western Meningitis 53
[64] Mefo 1999 Cameroon Middle Meningitis 99
[65] Soltani 2005 Tunisia Africa Northern 20
[66] Tall 1992 Burkina Faso Western Meningitis 285
[15] Thabet 2007 Tunisia Africa Northern 73
[67] WHO 1993 Mali and Niger Western Meningitis 426
The 37 articles included in this review are listed in the above table. Articles with overlapping data have two references listed in the 'reference' 
column but were extracted as one article in the review database.
CBM = confirmed bacterial meningitis; WHO = World Health Organization.BMC Medicine 2009, 7:47 http://www.biomedcentral.com/1741-7015/7/47
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hearing loss, vision loss, motor delay and seizures found
that 2% to 7% of children had any one of these specific
deficits [15]. A total of 14 articles including 1,463 children
with pneumococcal meningitis provided information on
CFR, which ranged from 9% to 67% (median 35%, IQR
29% to 44%).
Hib meningitis
Altogether, 9 studies had data on Hib meningitis seque-
lae, including a total of 798 children. In all, 4% to 44% of
survivors had neuropsychological sequelae (median 25%,
IQR 17% to 28%) (Table 5). The risk of sequelae ranged
from 2% to 26% for hearing loss (four studies), 1% to 3%
for vision loss (two studies), 2% to 32% for motor delay/
impairment (two studies), and 2% for seizures and 2% for
cognitive delay (one study each). Among 15 articles
including 1,373 children with Hib meningitis, the CFR
ranged from 4% to 41% (median 25%, IQR 17% to 36%).
Meningococcal meningitis
In all, 6 studies including a total of 701 children had data
on meningococcal meningitis sequelae with prevalence
estimates ranging from 3% to 21% (median 7%, IQR 5%
to 10%) (Table 5). Studies found hearing loss in 3% to 9%
of subjects (three studies), vision loss in 3% (one study),
behavioural problems in 1% (one study), motor impair-
ment in 1% to 2% (three studies), and seizures in 1% (two
studies). Among 8 studies following 1,065 children, the
CFR for meningococcal meningitis ranged from 1% to
13% (median 4%, IQR 3% to 6%).
Post-discharge sequelae and mortality
A total of 10 prospective studies evaluated children for
neuropsychological sequelae after discharge with CBM
(Table 6). The follow-up period ranged from 2 to 90
months after hospital discharge. Loss to follow-up of
patients ranged from 0% to 49% in eight studies and
could not be calculated in two studies. Post-discharge
mortality was reported in five studies and ranged from 0%
to 18% (median 10%). Sequelae were generally assessed
by clinical exam alone. One or more sequelae were found
in 3% to 47% of survivors (median 25%, IQR 13% to
33%). The two studies enrolling only children with TB
meningitis had sequelae estimates (24% and 32%) simi-
lar to studies including other bacterial pathogens [16,17].
Details of sequelae and mortality following discharge
with pneumococcal, Hib and meningococcal meningitis
are shown in Tables 7 and 8.
Discussion
In this review, we obtained comprehensive, up to date
information on the burden of sequelae associated with
bacterial meningitis in African children. We included 37
articles with sequelae data from 1980 to 2008, while an
earlier review based sequelae estimates only on 10 articles
published between 1970 and 2000 [3]. We estimated that
the median risk of in-hospital sequelae was 25% for pneu-
mococcal meningitis, 25% for Hib meningitis and 7% for
meningococcal meningitis, while the median risk of post-
discharge sequelae was 25% for all pathogens combined.
These estimates are slightly lower than those found in the
earlier African literature review [3], but the higher risk of
sequelae for pneumococcal and Hib meningitis compared
to meningococcal meningitis is consistent across the two
reviews. The median CFR estimates in our review were
35% and 25% for pneumococcal and Hib meningitis,
respectively, and thus slightly lower than the findings
from two previous reviews [3,9].
Few studies report on the nature of the neuropsychologi-
cal deficit beyond vision loss, hearing loss, seizures and
gross motor impairment. Our database included more
detailed and subtle neuropsychological deficit categories
in keeping with the World Health Organization (WHO)
international classification of functioning, disability and
health [7]. This highlighted gaps in knowledge for the
Table 3: Numbers of articles and cases reviewed by region
Region No. articles Total no. confirmed 
BM cases with follow-
up
Median no. confirmed 
BM cases with follow-
up (min, max)
Total no. evaluated 
for in-hospital 
sequelae
Total no. evaluated 
for post-discharge 
sequelae
Eastern Meningitis 6 584 81 (32, 224) 431 80
Middle Meningitis 3 340 99 (67, 174) 211 67
Western Meningitis 12 2,394 85 (23, 654) 1,353 168
Africa Eastern 3 284 83 (52, 149) 173 0
Africa Middle 2 494 (91, 403) 332 0
Africa Northern 9 1,793 118 (20, 697) 457 816
Africa Southern 2 140 (61, 79) 104 0
Total 37 6,029 3,061 1,131
A total of 3,061 survivors were evaluated for in-hospital sequelae. Most of the in-hospital sequelae data comes from the western Africa meningitis 
belt region. Much less data is available on post-discharge sequelae (n = 1,131 cases) because survivors of bacterial meningitis were lost to follow-up 
or died after hospital discharge. Most of the post-discharge data comes from the northern Africa region.
BM = bacterial meningitis.BMC Medicine 2009, 7:47 http://www.biomedcentral.com/1741-7015/7/47
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population studied: particularly lacking are data on cogni-
tive delay, speech/language problems and behavioural
problems.
In the studies we included, children with meningitis were
treated in hospital with antibiotics recommended by the
WHO (third generation cephalosporins or ampicillin plus
chloramphenicol), and in some cases steroids [18]. Our
findings suggest that even with appropriate antibiotic
treatment, up to half of all children affected by pneumo-
coccal and Hib meningitis die or experience clinically evi-
dent sequelae prior to hospital discharge. Increasing
resistance to penicillin and chloramphenicol among
pneumococcal strains may contribute to worse outcomes
Number of articles included in review by country and region Figure 2
Number of articles included in review by country and region.B
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Table 4: In-hospital outcomes for all causes of confirmed bacterial meningitis (CBM), by study
Reference Country No. CBM 
cases with 
known 
outcomes
CFR No. cases 
assessed for 
sequelae
HL (%) VL (%) CD (%) BP (%) MI (%) SZ (%) Any 
neuropsychological 
sequelae (%)
Bacterial 
pathogens 
studied
[43] Ethiopia 32 34% Spn, Hib, Nm, Gram 
negative enterococci
[45] Ethiopia 124 2% 121 3% 8% Nm
[54] Kenya 224 33% 150 27% Spn, Hib, non-typhi 
Salmonella, 
enterobacteria, 
Streptococcus group 
A or B and others
[62] Sudan 108 4% 104 3% 2% 5% Nm
[60] Sudan 43 19% 35 20% 11%a 26% Spn, Hib, Nm and 
others
[38] Cameroon 174 30% 121 17% Spn, Hib, Nm, 
Streptococcus, 
Staphylococcus, 
enterobacteria
[64] Cameroon 99 9% 90 1%a 1% 4% Spn, Hib, Nm
[63] Burkina Faso 53 75% Salmonella
[66] Burkina Faso 92 22% 72 7% 18% Hib
[37] Cote d'Ivoire 654 41% 380 6% 1% 2% 19% Spn, Hib
[53] Cote d'Ivoire 47 4% 45 7% Spn, Hib, Nm
[47] Ghana 67 27% 49 8% 2% 6%a 12% Spn, Hib, Nm
[67] Mali and 
Niger
426 37% 269 14% Spn, Hib, Nm and 
others
[55] Nigeria 124 27% 91 18% Spn, Hib, Nm and 
others
[40] Senegal 511 18% 420 21% Spn, Hib, Nm
[56] Angola 403 33% 270 24% Spn, Hib, Nm, 
othersB
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[57] Madagascar 83 31% 57 30% Spn, Hib, Nm
[51] Malawi 149 34% 92 20% Spn, Hib, Escherichia 
coli, Klebsiella, Group 
B Streptococcus, 
others
[52] Malawi 52 54% Salmonella
[44] Gabon 91 31% 62 18% Spn, Hib, Nm, 
Salmonella
[59] Algeria 57 4% 55 2% 2% 4% Hib
[16] Egypt 160 51% 78 8% 6% 18% Tuberculosis
[34] Morocco 118 1% 117 9% 3% 1% 2% 1% 21% Nm
[33] Morocco 141 9% 128 27% Spn
[15] Tunisia 73 14% 61 7% 2% 5% 3% 34% Spn
[42] South Africa 61 20% 49 33% 8% 37% 57% Spn, Hib, Nm, 
others
[14] South Africa 79 30% 55 5% 38% Spn
This table presents data extracted on in-hospital sequelae among studies with at least 25 CBM survivors and case fatality ratios (CFRs) among studies with at least 25 CBM cases for all bacterial 
causes combined. The proportion of meningitis survivors with any kind of neuropsychological sequelae, either one or more deficits, ranged from 4% to 57%. The in-hospital CFR ranged from 1% 
to 75%. In many studies, the proportion of children affected by specific types of sequelae was not given. Most sequelae were diagnosed by clinical exam only during the course of hospitalisation. 
aParalysis.
BP = behavioural problem; CD = cognitive delay; Hib = Haemophilus influenzae type b; HL = hearing loss; MI = motor impairment; Nm = Neisseria meningitidis; Spn = Streptococcus pneumoniae; SZ 
= seizures; VL = vision loss; 
Table 4: In-hospital outcomes for all causes of confirmed bacterial meningitis (CBM), by study (Continued)BMC Medicine 2009, 7:47 http://www.biomedcentral.com/1741-7015/7/47
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in some cases where access to third generation cepha-
losporins is limited. In our review, 15 of the articles (41%)
reported using third generation cephalosporins as a first-
line antibiotic in at least some cases. There were no clear
trends in in-hospital sequelae risk over time likely because
of relatively little heterogeneity in first-line therapies dur-
ing the time period studied. Updated WHO guidelines
promote the use of ceftriaxone in epidemic and non-epi-
demic settings as the first-line therapy for bacterial menin-
gitis in Africa [19].
Further, a small number of studies included in the review
show an increased risk of death and a 25% risk of long-
term disability subsequent to discharge in children hospi-
talised for bacterial meningitis. The median estimates for
in-hospital and post-discharge sequelae in our review did
not differ greatly even though some sequelae following
bacterial meningitis are expected to resolve over time [20].
African children experience the highest incidence rates for
pneumococcal and Hib meningitis globally [9]. The high
incidence, case fatality and sequelae risk due to bacterial
meningitis underscore the public health importance of
this disease and its poor outcome among children in
Africa.
The articles included in this review represent 21 of the 52
African countries. In all, 44% of children with in-hospital
outcome data were from the western Africa meningitis
belt region and 72% of those with post-discharge data
were from the northern Africa region. There were no
major regional differences for study estimates of in-hospi-
tal sequelae risk associated with each of the three main
bacteria (Table 5). The post-discharge sequelae studies
had very few subjects overall and represent only seven
countries. Among the post-discharge studies, the two
northern Africa studies found the lowest risk of sequelae
associated with individual bacterial pathogens (Table 7).
Box plots of proportion of survivors with in-hospital sequelae Figure 3
Box plots of proportion of survivors with in-hospital sequelae. This figure presents box plots of the range of estimates 
for any in-hospital neuropsychological sequelae by pathogen and for all causes of confirmed bacterial meningitis (CBM) com-
bined. The upper border of the shaded box is the value of the 75th percentile and the lower border of the shaded box is the 
25th percentile, and these two values define the interquartile range (IQR). The vertical 'whiskers' represent the values 1.5 IQRs 
above the 75th percentile and 1.5 IQRs below the 25th percentile. Any data points that are beyond the whiskers appear as out-
liers (dots). The median estimate for each group is represented by the horizontal line within the shaded box and the number 
above the horizontal line.
Spn = Streptococcus pneumoniae, Hib = Haemophilus influenzae type b, Nm = Neiserria meningitidis
25%  25% 
18% 
7% 
    Spn           Hib           Nm      All bacteria BMC Medicine 2009, 7:47 http://www.biomedcentral.com/1741-7015/7/47
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Our strict case definition for confirmed bacterial meningi-
tis led to the exclusion of 42 articles with data on neu-
ropsychological sequelae (49% of 86 studies). This
definition was selected to ensure that cases of viral menin-
gitis, which are generally less severe, were excluded and to
enable us to calculate pathogen-specific estimates for
sequelae and mortality. However, this methodological
choice limits the generalisibility of our findings, given the
small number and regional provenance of the remaining
studies.
Many African children have limited access to medical care.
Our review includes only patients who were admitted to a
hospital, of which 77% were tertiary referral or teaching
hospitals, had diagnostic testing for bacterial meningitis
and received appropriate antibiotic therapy. These chil-
dren are likely to have improved outcomes compared to
children treated in lower-level facilities, where antibiotics
are not always available, and children who did not reach
medical care. Thus, our review likely underestimates the
overall burden of sequelae and mortality in African chil-
dren with bacterial meningitis.
This review identified very few studies with data on post-
discharge outcomes of bacterial meningitis among African
children. High loss to follow-up in these studies may lead
to biased results, while small sample sizes limit the preci-
sion of our findings. However, a post-discharge study of
children with pneumococcal meningitis from Bangladesh
found that 11% died and 49% had long-term sequelae
detectable 12 to 24 months post infection [21]. This study
had a low loss to follow-up rate of 11%, and the propor-
tion of children affected was on par with a similar study
from The Gambia [22]. A recent review of the global bur-
den of meningitis sequelae was conducted and found the
highest risk of long-term sequelae in Africa compared to
all other regions (Karen Edmond, senior lecturer in infec-
tious disease epidemiology, London School of Hygiene
and Tropical Medicine, personal communication). Lim-
ited access to health care and poor health indicators make
many African children highly susceptible to adverse out-
comes following bacterial meningitis.
Further, the social and economic burden of survivors with
neuropsychological sequelae is little studied in Africa.
Most studies included in this review diagnosed sequelae
based on clinical exam alone and thus represent profound
deficits that would severely affect a child's developmental
potential. In the absence of follow-up specialty services
for affected children, major sequelae can result in lifelong
disability. This in turn affects the disabled child's entire
family, as caregivers must choose between caring for the
disabled child, providing for siblings and working outside
the home to supplement the family's income [21]. In a
Box plots of in-hospital case fatality ratios Figure 4
Box plots of in-hospital case fatality ratios.
Spn = Streptococcus pneumoniae, Hib = Haemophilus influenzae type b, Nm = Neiserria meningitidis
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Table 5: In-hospital outcomes for the three main bacterial pathogens, by study
Reference Bacteria Country No. of CBM 
cases
In-hospital 
CFR
Total no. 
cases 
assessed for 
sequelae
HL (%) VL (%) CD (%) BP (%) MI (%) SZ (%) Any 
neuropsycho
logical 
sequelae (%)
[38] Spn Cameroon 74 39% 45 16%
[37] Spn Cote d'Ivoire 330 60% 132 25%
[47] Spn Ghana 33 36%
[67] Spn Mali and 
Niger
115 67% 38 21%
[22] Spn The Gambia 134 48%
[57] Spn Madagascar 40 40%
[51] Spn Malawi 62 44% 32 25%
[44] Spn Gabon 42 29% 30 20%
[33] Spn Morocco 141 9% 128 27%
[15] Spn Tunisia 73 14% 61 7% 2% 5% 3% 34%
[41] Spn Egypt 106 27%
[14] Spn South Africa 79 30% 55 5% 38%
[54] Spn Kenya 92 36% 59 32%
[40] Spn Senegal 142 32% 96 28%
[54] Hib Kenya 77 17% 64 25%
[60] Hib Sudan 25 16%
[38] Hib Cameroon 53 25% 40 15%
[37] Hib Cote d'Ivoire 314 21% 248 6% 1% 2% 17%
[36] Hib The Gambia 77 25%
[67] Hib Mali and 
Niger
133 36% 85 28%
[40] Hib Senegal 216 18% 178 6% 3% 2% 27%
[22] Hib The Gambia 123 27%
[66] Hib Burkina Faso 92 22% 72 7% 18%
[57] Hib Madagascar 35 29% 25 44%
[51] Hib Malawi 44 41%
[44] Hib Gabon 36 31%
[59] Hib Algeria 57 4% 55 2% 2% 4%
[41] Hib Egypt 56 30%
[42] Hib South Africa 35 11% 31 26% 32% 32%a
[45] Nm Ethiopia 124 2% 121 3% 8%
[62] Nm Sudan 108 4% 104 3% 2% 5%
[64] Nm Cameroon 77 5% 73 1%b 1% 3%
[67] Nm Mali and 
Niger
161 13% 140 5%
[40] Nm Senegal 153 5% 146 10%
[41] Nm Egypt 267 6%
[34] Nm Morocco 118 1% 117 9% 3% 1% 2% 1% 21%
[50] Nm Tunisia 57 4%
This table presents the in-hospital sequelae and case fatality ratio (CFR) data available for 25 or more children diagnosed or surviving meningitis caused by 1 of the 3 main bacterial causes. 
Sequelae prevalences ranged from 16% to 38% for Spn meningitis, 4% to 44% for Hib meningitis and 3% to 21% for Nm meningitis.
aEstimated 'Any neuropsychological sequelae' based on single sequelae type with largest proportion; bparalysis.
BP = behavioural problem; CBM, confirmed bacterial meningitis; CD = cognitive delay; Hib = Haemophilus influenzae type b; HL = hearing loss; MI = motor impairment; Nm = Neisseria meningitidis; 
Spn = Streptococcus pneumoniae; SZ = seizures; VL = vision loss.B
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Table 6: Post-discharge (PD) outcomes for all causes of confirmed bacterial meningitis (CBM), by study
Reference Country No. cases 
discharged
PD CFR Average 
follow-up 
time, months
Total no. 
assessed for 
sequelae
HL (%) VL (%) CD (%) SLD (%) BP (%) MI (%) SZ (%) Any 
neuropsychologi
cal sequelae (%)
Bacterial 
pathogens 
studied
[50] Tunisia 85 60 82 13% Spn, Hib, Nm
[41] Egypt 367 0% 3 367 2% 0% 0% 1% 3% Spn, Hib, Nm
[35] Nigeria 47 0% 47 15% 23% Spn, Hib, Nm, 
Klebsiella and 
others
[16] Egypt 78
(2 to 24)
78 10% 10% 24% Tuberculosis
[17] Egypt 289 12 289 8% 7% 32% Tuberculosis
[49] Ethiopia 53 34% 34%a Spn, Hib, Nm, 
others
[36] The 
Gambia
58 16% 8 48 13% Hib
[48] Cameroon 14 67 13% 3% 4% 4% 2% 3%b 7% 25% Spn, Hib, Nm, 
others
[60] Sudan 34 10%
(3 to 48)
27 22% 7% 7% 7% 11% 33% Spn, Hib, Nm 
and others
[22] The 
Gambia
160 18%
(11 to 90)
73 33% 11% 22% 27%c 19% 47% Spn, Hib
The outcomes of children treated for all causes of CBM are shown for studies with >25 subjects. The number of cases discharged was calculated based on the number of CBM cases included in the study minus 
the number of children reported who died in-hospital. Post-discharge case fatality ratio (CFR) was calculated as the number of deaths after discharge divided by the number of cases with known follow-up; the 
denominator does not include cases lost to follow-up. Sequelae prevalence in children followed-up ranged from 3% to 47%. Half of the studies also had information on post-discharge CFR, which ranged from 
0% to 18% in the period 3 to 90 months after illness.
aEstimated 'Any neuropsychological sequelae' based on single sequelae type with largest proportion; bparalysis; cgross motor impairment.
BP = behavioural problem; CD = cognitive delay; Hib = Haemophilus influenzae type b; HL = hearing loss; MI = motor impairment; Nm = Neisseria meningitidis; Spn = Streptococcus pneumoniae; SLD = speech or 
language disorder; SZ = seizures; VL = vision loss.B
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Table 8: Overview of sequelae and mortality by bacterial pathogen and for all-cause confirmed bacterial meningitis (CBM)
Type of bacteria No. of studies 
with in-hospital 
data
Total no. cases In-hospital CFR: 
median (min, max)
% With any in-
hospital sequelae: 
median (min, max)
No. of studies 
with post-
discharge data
Total no. cases 
discharged
% Cases died after 
discharge: median 
(min, max)
% With any post-
discharge 
sequelae: median 
(min, max)
Pneumococcus 14 1,463 35% 
(9% to 67%)
25% 
(16% to 38%)
3 147 0%, 22.5%a 5%, 41%, 58%a
Hib 15 1,373 25% 
(4% to 41%)
25% 
(4% to 44%)
3 187 0%, 14%, 16%a 0%, 13%, 38%a
Meningococcus 8 1,065 4% 
(1% to 13%)
7% 
(3% to 21%)
23 0 6 0 % a 3%, 9%a
All bacteria 27 4,245 27% 
(1% to 75%)
18% 
(4% to 57%)
10 1,118 0% 
(0% to 18%)
25% 
(3% to 47%)
aActual values.
CFR = case fatality ratio; Hib = Haemophilus influenzae type b.
Table 7: Post-discharge outcomes for the three main bacterial pathogens, by study
Reference Bacteria Country No. cases 
discharged
PD CFR Average 
follow-up 
time, months 
(or range)
Total no. 
assessed for 
sequelae
HL (%) VL (%) CD (%) SLD (%) BP (%) MI (%) SZ (%) Any 
neuropsychologic
al sequelae (%)
[41] Spn Egypt 77 0% 3 77 5% 0% 0% 0% 5%
[48] Spn Cameroon 14 34 21% 6% 9% 9% 3% 6%a 9% 41%
[22] Spn The Gambia 70 23%
(11 to 90)
31 48% 23% 32% 48%b 10% 58%
[41] Hib Egypt 39 0% 3 39 0% 0% 0% 0% 0%
[36] Hib The Gambia 58 16% 8 48 13%
[22] Hib The Gambia 90 14%
(11 to 90)
42 21% 2% 14% 12%b 26% 38%
[50] Nm Tunisia 55 60 55 9%
[41] Nm Egypt 251 0% 3 251 2% 0% 0% 1%a 3%
This table shows the findings of studies with post-discharge follow-up of at least 25 children following confirmed bacterial meningitis (CBM) caused by 1 of the 3 main bacterial pathogens. The number of 
cases discharged was calculated based on the number of CBM cases included in the study minus the number of children reported who died in hospital. Post-discharge case fatality ratio (CFR) was calculated 
as the number of deaths after discharge divided by the number of cases with known follow-up; the denominator does not include cases lost to follow-up.
aParalysis; bgross motor impairment.
BP = behavioural problem; CD = cognitive delay; Hib = Haemophilus influenzae type b; HL = hearing loss; MI = motor impairment; Nm = Neisseria meningitidis; Spn = Streptococcus pneumoniae; SLD = speech 
or language disorder; SZ = seizures; VL = vision loss.BMC Medicine 2009, 7:47 http://www.biomedcentral.com/1741-7015/7/47
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South African study following children with TB meningi-
tis and their families, 35% of previously-employed moth-
ers had to stop working and one in five families
experienced a financial loss as a result of the child's ill-
ness; half of the schoolgoing children failed at least one
school grade [23]. The societal burden of hearing loss is
best documented, and in several countries meningitis has
been consistently found to be a common cause of pro-
found hearing loss [24-26].
Our review provides no information on the effect of HIV
on meningitis outcomes. HIV may shift the relative fre-
quencies of bacterial pathogens causing meningitis and
contribute to childhood malnutrition, which was associ-
ated with worse prognosis in our risk factor analysis. A
study from Malawi found a higher rate of mortality and
recurrent disease in HIV-infected children with bacterial
meningitis [27]. Another study from South Africa found a
higher rate of pneumococcal meningitis and poor out-
comes in HIV-infected children [28]. More research is
needed on the effects of the HIV pandemic on bacterial
meningitis outcomes, particularly in the high HIV preva-
lence areas of middle, southern and eastern Africa.
The three main bacterial causes of postneonatal child-
hood meningitis are all vaccine preventable. Even with
appropriate treatment, pneumococcal and Hib meningitis
kill approximately one third of affected children and
cause clinically evident sequelae in a quarter of survivors
prior to hospital discharge. Hib conjugate vaccine use has
nearly eliminated Hib meningitis in many African coun-
tries [29,30]. In Uganda, it was estimated that the vaccine
prevents 1,000 cases of severe meningitis sequelae each
year in the country's population of 5.3 million children
under 5 years of age [29]. Pneumococcal conjugate vac-
cines (PCVs) are effective against invasive pneumococcal
disease in African children, including meningitis [31]. In
light of the high incidence of pneumococcal disease and
its poor outcomes, these vaccines could prevent substan-
tial numbers of meningitis-associated disabilities and
deaths. PCV introduction into GAVI-eligible countries is
underway and subsequent health and economic benefits
will be closely monitored. Finally, though mortality and
sequelae risk following meningococcal meningitis are not
as high as with pneumococcal or Hib meningitis, the
absolute numbers of sequelae and deaths occurring dur-
ing meningococcal meningitis epidemics are tremendous.
The epidemic potential of meningococcal meningitis has
focused much attention on the introduction of meningo-
coccal polysaccharide and conjugate vaccines in countries
of the African meningitis belt. In addition, the related clin-
ical syndrome of meningococcal sepsis, a fulminant dis-
ease that has been associated with CFRs of up to 80%,
could decrease with the expanded use of meningococcal
vaccine [32].
Evaluations of the health impact and cost effectiveness of
conjugate vaccines should incorporate the economic and
social impact of meningitis morbidity and mortality on
families, many of which have little financial reserve to
care for a child with a long-term disability. This review
mainly includes children treated at tertiary care facilities
and therefore underestimates the sequelae and mortality
risk associated with bacterial meningitis. Thus, the true
cost of meningitis and the true benefit of bacterial conju-
gate vaccines are likely to be tremendous.
Conclusion
Bacterial meningitis is a serious infection that has high
risk of sequelae as well as mortality in African children.
Even with appropriate treatment, pneumococcal and Hib
meningitis kill approximately one third of affected chil-
dren and cause clinically evident sequelae in a quarter of
survivors prior to hospital discharge. The three leading
causes of bacterial meningitis in childhood are vaccine
preventable, and the regular use of these conjugate vac-
cines would reduce the high burden of morbidity and
mortality in both epidemic and endemic settings.
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